Clinical and Prognostic Factors in Patients with IgG4-Related Kidney Disease
Copyright © 2023 by the American Society of Nephrology..
BACKGROUND: IgG4-related kidney disease is a major manifestation of IgG4-related disease, a systemic fibroinflammatory disorder. However, the clinical and prognostic kidney-related factors in patients with IgG4-related kidney disease are insufficiently defined.
METHODS: We conducted an observational cohort study using data from 35 sites in two European countries. Clinical, biologic, imaging, and histopathologic data; treatment modalities; and outcomes were collected from medical records. Logistic regression was performed to identify the possible factors related to an eGFR ≤30 ml/min per 1.73 m 2 at the last follow-up. Cox proportional hazards model was performed to assess the factors associated with the risk of relapse.
RESULTS: We studied 101 adult patients with IgG4-related disease with a median follow-up of 24 (11-58) months. Of these, 87 (86%) patients were male, and the median age was 68 (57-76) years. Eighty-three (82%) patients had IgG4-related kidney disease confirmed by kidney biopsy, with all biopsies showing tubulointerstitial involvement and 16 showing glomerular lesions. Ninety (89%) patients were treated with corticosteroids, and 18 (18%) patients received rituximab as first-line therapy. At the last follow-up, the eGFR was below 30 ml/min per 1.73 m 2 in 32% of patients; 34 (34%) patients experienced a relapse, while 12 (13%) patients had died. By Cox survival analysis, the number of organs involved (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.01 to 1.55) and low C3 and C4 concentrations (HR, 2.31; 95% CI, 1.10 to 4.85) were independently associated with a higher risk of relapse, whereas first-line therapy with rituximab was protective (HR, 0.22; 95% CI, 0.06 to 0.78). At their last follow-up, 19 (19%) patients had an eGFR ≤30 ml/min per 1.73 m 2 . Age (odd ratio [OR], 1.11; 95% CI, 1.03 to 1.20), peak serum creatinine (OR, 2.74; 95% CI, 1.71 to 5.47), and serum IgG4 level ≥5 g/L (OR, 4.46; 95% CI, 1.23 to 19.40) were independently predictive for severe CKD.
CONCLUSIONS: IgG4-related kidney disease predominantly affected middle-aged men and manifested as tubulointerstitial nephritis with potential glomerular involvement. Complement consumption and the number of organs involved were associated with a higher relapse rate, whereas first-line therapy with rituximab was associated with lower relapse rate. Patients with high serum IgG4 concentrations (≥5 g/L) had more severe kidney disease.
| Errataetall: |
CommentIn: Clin J Am Soc Nephrol. 2023 Aug 1;18(8):994-996. - PMID 37418275 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Clinical journal of the American Society of Nephrology : CJASN - 18(2023), 8 vom: 01. Aug., Seite 1031-1040 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 09.08.2023 Date Revised 12.10.2023 published: Print-Electronic CommentIn: Clin J Am Soc Nephrol. 2023 Aug 1;18(8):994-996. - PMID 37418275 Citation Status MEDLINE |
|---|
| doi: |
10.2215/CJN.0000000000000193 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357853237 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357853237 | ||
| 003 | DE-627 | ||
| 005 | 20231226073503.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2215/CJN.0000000000000193 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357853237 | ||
| 035 | |a (NLM)37283461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chaba, Anis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and Prognostic Factors in Patients with IgG4-Related Kidney Disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2023 | ||
| 500 | |a Date Revised 12.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin J Am Soc Nephrol. 2023 Aug 1;18(8):994-996. - PMID 37418275 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by the American Society of Nephrology. | ||
| 520 | |a BACKGROUND: IgG4-related kidney disease is a major manifestation of IgG4-related disease, a systemic fibroinflammatory disorder. However, the clinical and prognostic kidney-related factors in patients with IgG4-related kidney disease are insufficiently defined | ||
| 520 | |a METHODS: We conducted an observational cohort study using data from 35 sites in two European countries. Clinical, biologic, imaging, and histopathologic data; treatment modalities; and outcomes were collected from medical records. Logistic regression was performed to identify the possible factors related to an eGFR ≤30 ml/min per 1.73 m 2 at the last follow-up. Cox proportional hazards model was performed to assess the factors associated with the risk of relapse | ||
| 520 | |a RESULTS: We studied 101 adult patients with IgG4-related disease with a median follow-up of 24 (11-58) months. Of these, 87 (86%) patients were male, and the median age was 68 (57-76) years. Eighty-three (82%) patients had IgG4-related kidney disease confirmed by kidney biopsy, with all biopsies showing tubulointerstitial involvement and 16 showing glomerular lesions. Ninety (89%) patients were treated with corticosteroids, and 18 (18%) patients received rituximab as first-line therapy. At the last follow-up, the eGFR was below 30 ml/min per 1.73 m 2 in 32% of patients; 34 (34%) patients experienced a relapse, while 12 (13%) patients had died. By Cox survival analysis, the number of organs involved (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.01 to 1.55) and low C3 and C4 concentrations (HR, 2.31; 95% CI, 1.10 to 4.85) were independently associated with a higher risk of relapse, whereas first-line therapy with rituximab was protective (HR, 0.22; 95% CI, 0.06 to 0.78). At their last follow-up, 19 (19%) patients had an eGFR ≤30 ml/min per 1.73 m 2 . Age (odd ratio [OR], 1.11; 95% CI, 1.03 to 1.20), peak serum creatinine (OR, 2.74; 95% CI, 1.71 to 5.47), and serum IgG4 level ≥5 g/L (OR, 4.46; 95% CI, 1.23 to 19.40) were independently predictive for severe CKD | ||
| 520 | |a CONCLUSIONS: IgG4-related kidney disease predominantly affected middle-aged men and manifested as tubulointerstitial nephritis with potential glomerular involvement. Complement consumption and the number of organs involved were associated with a higher relapse rate, whereas first-line therapy with rituximab was associated with lower relapse rate. Patients with high serum IgG4 concentrations (≥5 g/L) had more severe kidney disease | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Devresse, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Audard, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Boffa, Jean Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Karras, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Cartery, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Deltombe, Clément |e verfasserin |4 aut | |
| 700 | 1 | |a Chemouny, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Contamin, Claudine |e verfasserin |4 aut | |
| 700 | 1 | |a Courivaud, Cecile |e verfasserin |4 aut | |
| 700 | 1 | |a Duquennoy, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Joly, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Goumri, Nabila |e verfasserin |4 aut | |
| 700 | 1 | |a Hanouna, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Halimi, Jean Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Plaisier, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Hamidou, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Landron, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Launay, David |e verfasserin |4 aut | |
| 700 | 1 | |a Lebas, Celine |e verfasserin |4 aut | |
| 700 | 1 | |a Legendre, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Masseau, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Mathian, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Mercadal, Lucile |e verfasserin |4 aut | |
| 700 | 1 | |a Morel, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Mutinelli-Szymanski, Prisca |e verfasserin |4 aut | |
| 700 | 1 | |a Palat, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Pennaforte, Jean-Loup |e verfasserin |4 aut | |
| 700 | 1 | |a Peraldi, Marie Noelle |e verfasserin |4 aut | |
| 700 | 1 | |a Pozdzik, Agnieszka |e verfasserin |4 aut | |
| 700 | 1 | |a Schleinitz, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Thaunat, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Titeca-Beauport, Dimitri |e verfasserin |4 aut | |
| 700 | 1 | |a Mussini, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Touati, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Prinz, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Faller, Anne Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Vilaine, Eve |e verfasserin |4 aut | |
| 700 | 1 | |a Ferlicot, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Von-Kotze, Clarissa |e verfasserin |4 aut | |
| 700 | 1 | |a Belliere, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Olagne, Jerome |e verfasserin |4 aut | |
| 700 | 1 | |a Mesbah, Rafik |e verfasserin |4 aut | |
| 700 | 1 | |a Snanoudj, Renaud |e verfasserin |4 aut | |
| 700 | 1 | |a Nouvier, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Ebbo, Mikael |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidan, Mohamad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical journal of the American Society of Nephrology : CJASN |d 2006 |g 18(2023), 8 vom: 01. Aug., Seite 1031-1040 |w (DE-627)NLM172123720 |x 1555-905X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:1031-1040 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2215/CJN.0000000000000193 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 8 |b 01 |c 08 |h 1031-1040 | ||